Table 2.
Summary of SARS-CoV-2 commercial antibody assay kit performance studies conducted by Public Health England, UK.
| Commercial Assay | Samples Tested * | Sensitivity (95% CI) | Specificity (95% CI) |
|---|---|---|---|
| Beckman Coulter Access Anti-SARS-CoV-2 IgG assay | 100 pos, 499 neg | 76.5% (66.0–85.0) | 99.3% (97.8–99.8) |
| Siemens Atellica-IM SARS-CoV-2 Total (COV2T) assay | 100 pos, 499 neg | 89.4% (80.8–95.0) | 100% (99.1–100) |
| Ortho Clinical Diagnostics Vitros Anti-SARS -CoV-2 assay | 100 pos, 491 neg | 91.8% (83.8–96.6) | 99.5% (98.2–99.9) |
| DiaSorin LIAISON SARS-CoV-2 S1/S2 IgG assay | 100 pos, 472 neg | 69.4% (58.5–79.0) | 97.7% (95.8–99.0) |
| Euroimmun Anti-SARS-CoV-2 ELISA (IgG) assay | 93 pos, 499 neg | 73.4% (62.3–82.7) | 99.0% (97.5–99.7) |
| Abbott SARS-CoV-2 IgG assay | 96 pos, 760 neg | 93.9% (86.3–98.0) | 100% (99.1–100) |
| Roche Elecsys Anti-SARS-CoV-2 EIA | 93 pos, 472 neg | 86.1% (76.5–92.8) | 100% (99.1–100) |
| Siemens Atellica-IM SARS-CoV-2 (sCOVG) assay | 115 pos, 500 neg | 72.5% (61.4–81.9) | 100% (98.9–100) |
* Convalescent SARS-CoV-2 blood samples collected 14 days or longer following symptom onset. Data are unique for each assay as the samples used were not all the same. The data used are as published by Public Health England and are available on the website http://www.gov.uk/government/publications/COVID-19-laboratory-evaluations-of-serological-assays#history (accessed on 10 March 2021) [52].